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OBJECTIVE
Since patients with type 2 diabetes and positive for type 1 diabetes–specific anti-
bodies have wide variations in BMI, this study evaluated whether the frequency
and pattern of islet autoantibody positivity is related to BMI.
RESEARCH DESIGN AND METHODS
Clinical and biochemical characteristics and islet autoantibodies including GAD
and protein tyrosine phosphatases islet antigen-2 (IA-2)IC and IA-2(256–760) were
evaluated in 1,850 patients with type 2 diabetes from the Non–Insulin Requir-
ing Autoimmune Diabetes study cohort. BMI was evaluated in all patients, who
were then subdivided in three groups according to BMI (<25, ‡25 to <30, and
‡30 kg/m2).
RESULTS
Out of 1,850, 120 (6.5%) patients were positive for at least one of the following
antibodies: GAD (4.1%), IA-2(256–760) (3.3%), or IA-2IC (1.1%). GAD and IA-2IC anti-
bodies showed decreasing frequencies with increasing BMI (P < 0.0001 and
0.0006, respectively, for trend); in contrast, the frequency of IA-2(256–760) anti-
bodies increased with increasing BMI (P = 0.005 for trend). Patients with type 2
diabetes positive for IA-2(256–760) alone showed a phenotype resembling classical
obese type 2 diabetes, with higher BMI, waist circumference, and uric acid (P <
0.005 for all), lower thyroid peroxidase antibodies, and lower progression to in-
sulin requirement than GAD antibody–positive patients (P = 0.04 and P = 0.0005,
respectively).
CONCLUSIONS
The IA-2(256–760) antibody appears to represent an antibody marker that mainly
identifies a clinical phenotype very similar to obese type 2 diabetes, suggesting a
possible different pathogenetic mechanism.
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The presence of antibodies specific to
type 1 diabetes was first described in
patients with type 2 diabetes by Irvine
et al. (1) in a subgroup of patients who
were treated with oral hypoglycemic
agents. These patients, known by the
acronym of latent autoimmune diabetes
in adults (LADA), show a slower progres-
sion to insulin requirement than pa-
tients with type 1 diabetes (2) but
share a similar antibody pattern, albeit
with significant quantitative differences
(3,4). In islet autoantibody–positive pa-
tients clinically diagnosed as type 2 di-
abetic, GAD autoantibodies (GADAs)
represent the marker most frequently
detected (4,5), whereas tyrosine phos-
phatase islet antigen-2 antibodies (IA-
2As) directed against the COOH portion
of the protein were initially detected in a
low number of patients (4).With respect
to IA-2 autoantibodies, distinct con-
structs of the IA-2 were shown indeed
to account for different immunoreac-
tivities in autoimmune diabetes. The
IA-2IC(605–979) construct showed the high-
est sensitivity when used to evaluate IA-
2 immunoreactivity in patients with
newly diagnosed type 1 diabetes (6),
whereas this construct was less frequent
than the IA-2 fragment IA-2(256–760) in
patients with type 2 diabetes. Indeed,
in the Non–Insulin Requiring Auto-
immune Diabetes (NIRAD) study (7),
IA-2(256–760)A were detected in ;30%
of GADA-positive patients, and interest-
ingly, in 3.4% of GADA and of IA-2IC
antibody–negative patients (7), thus
identifying a subset of type 2 diabetic
subjects with signs of ongoing islet
autoimmunity.
The presence of insulin antibodies,
which represents a specific marker of
diabetes in young patients, is inversely
related to age and is rare in adults; these
antibodies are therefore unlikely to
be useful for screening for antibody-
positive patients with type 2 diabetes
(8–10). Zinc transporter 8 (ZnT8) auto-
antibodies have recently been consid-
ered as an additional marker of islet
autoimmunity in patients with type 2 di-
abetes (11,12), although their preva-
lence is quite low in these patients (11).
In our previous studies (12,13), we
demonstrated a great deal of heteroge-
neity within the type 2 diabetic islet
autoantibody-positive population in terms
of phenotypic, genetic, immunological,
andbiochemical characteristics. Specifically,
BMI varied widely, ranging from values be-
low normality up to extreme obesity. Re-
cent studies provided evidence to
support the hypothesis that chronic in-
flammation that characterizes visceral
obesity could alsodetermine acquired au-
toimmunity against b-cells (14).
The correlation between BMI and the
risk of autoimmune diseases has been
recently evaluated (15). T helper (Th)
17 cell expansion seems to be a prom-
inent element of proinflammatory dis-
eases in obesity and has been found to
be connected to autoimmune diseases
such as rheumatoid arthritis, ankylosing
spondylitis, systemic lupus erythemato-
sus, multiple sclerosis, psoriasis, and
type 1 diabetes. The unstable Th17 cells
are likely converted into either the Th1
or Th2 phenotype, causing Th1- or Th2-
mediated autoimmune diseases. In light
of these findings and in an attempt to
further characterize this heterogeneous
form of diabetes, we aimed at evaluat-
ing whether the frequency and pattern
of the humoral islet immune response in
autoantibody-positive patients with
type 2 diabetes is related to BMI.
RESEARCH DESIGN AND METHODS
A total of 1,850 patients, all recruited in
central Italy (13) from the NIRAD study
cohort of 5,330 consecutive cases of
type 2 diabetes (13), was evaluated in
the current study.
Inclusion criteria for the NIRAD study
were: 1) diagnosis of diabetes according
to the American Diabetes Association
(16); 2) no insulin requirement and no
evidence of ketosis from diagnosis to
screening time; and 3) disease duration
between 6 months and 5 years. Exclu-
sion criteria included: 1) prior insulin
therapy, 2) pregnancy; and 3) the pres-
ence of any other severe diseases.
The following parameters were evalu-
ated: clinical and biochemical character-
istics (age at diagnosis, duration of
disease, BMI,waist circumference, fasting
blood glucose, total and HDL cholesterol,
triglycerides, HbA1c, and uric acid) as well
as autoantibodies directed against GAD,
IA-2IC(605–979), and IA-2(256–760) proteins.
ZnT8, tissue transglutaminase (tTG),
and thyroid peroxidase (TPO) antibodies
were analyzed only in patients positive
for GADA and/or IA-2A and in a twofold
number of type 2 diabetic patients
matched for sex and duration of disease.
GADAs as well as IA-2IC, IA-2(256–760),
ZnT8, and tTG antibodies weremeasured
by previously described immunoradio-
binding assays using the correspondent
in vitro translated [35S]methionine-
labeled protein (7,13,17,18).
As far as the IA-2(256–760) antibodies
assay is concerned, the cutoff defined
as values .99th percentile of 360
healthy control sera is 0.046. The intra-
and interassay coefficients of variation
are 5.7 and 10.3%, respectively. The
specificity is 99% and the sensitivity is
30% for type 1 diabetes ,18 years of
age and 40% for type 1 diabetes .18
years of age. TPO antibodies were mea-
suredusinga radioimmunoassay (Medipan,
Berlin, Germany) (13).
BMI was evaluated in all patients,
who were then subdivided in three
groups according to BMI (,25, $25 to
,30, and $30 kg/m2). When BMI sub-
groups were considered, 331 patients
had BMI ,25 kg/m2, 722 patients had
BMI $25 to ,30 kg/m2, and 797 pa-
tients had BMI $30 kg/m2.
Clinical and biochemical characteris-
tics and the presence and levels of anti-
bodies were described for each of the
three BMI subgroups and compared.
A subgroup of autoantibody-positive
patients (n = 53) was followed-up for 7
years from the time of first antibody
screening to evaluate their progression
toward insulin requirement. Initiation of
insulin therapy was part of a protocol
treatment in the NIRAD study, and the
participating centers were blinded to
antibody results. Insulin requirement
was defined as the clinical need to start
insulin therapy in patients whose glyce-
mic control, measured at each sched-
uled visit, became unacceptable (HbA1c
$58 mmol/mol or $7.5%) despite
treatment with a maximally tolerated
combination of insulin sensitizers (met-
formin and/or thiazolidinediones) and
sulfonylurea therapy.
The study was approved by all local
ethics committees, and written in-
formed consent was obtained from all
patients.
Statistical Analysis
Statistical analysis was performed using
SAS v9.3 software. Data were expressed
as means 6 SD. The Shapiro-Wilk test
was used to test the normality of distri-
bution of continuous variables. When
data were not normally distributed, loga-
rithmic transformation was performed.
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For normally distributed continuous vari-
ables, mean values between two groups
were compared by Student t test. Fre-
quency differences were compared using
the x2 test (with Yates continuity correc-
tion) or Fisher exact test when appropri-
ate. The Cochran-Armitage test was used
to test for trends between the frequen-
cies of GADA, IA-2(256–760)A, and IA-2ICA in
each BMI subgroup. A Venn diagram was
used to show the autoantibody frequen-
cies. A P value ,0.05 was considered as
statistically significant.
RESULTS
Of the 1,850 patients with type 2 diabe-
tes, 120 (6.5%) were positive for at least
one of the autoantibodies to GAD
(4.1%), IA-2(256–760) (3.3%), or IA-2IC
(1.1%).
Figure 1 shows the distribution of
GAD, IA-2(256–760) and IA-2IC autoanti-
body frequencies according to BMI.
Overall, the frequency of GADA, IA-
2(256–760)A, and IA-2ICA significantly de-
creased as patients’ BMI increased (P ,
0.0001, P = 0.014, and P , 0.0001, re-
spectively, for trends across BMI sub-
groups). GADA was the most frequent
antibody in patients with BMI,25 kg/m2,
whereas IA-2(256–760)A was the most fre-
quent in patients with BMI$30 kg/m2.
However, when only the 120 GAD
and/or IA-2(256–760) and/or IA-2IC
antibody–positive patients were consid-
ered, GADA and IA-2ICA showed decreas-
ing frequencies with increasing BMI (P,
0.0001 and P = 0.0006, respectively, for
trend), while IA-2(256–760)A frequency
significantly increased with increasing
BMI (P = 0.005 for trend), with these
antibodies becoming the most frequent
antibody and, in;70% of cases, the only
islet autoantibody in patients with a BMI
$30 kg/m2 (Fig. 2).
The antibody combinations in auto-
antibody-positive patients according to
BMI is shown in Fig. 3. Among 49 pa-
tients with BMI ,25 kg/m2, 25 were
positive for GADA alone, and 11 were
positive for all three antibodies; con-
versely, in patients with BMI $30 kg/m2,
7 patients were positive for GADA, and
1 was positive for the three antibodies.
Six patients with BMI ,25 kg/m2 and
21 patients with BMI $30 kg/m2 were
positive only for IA-2(256–760)A.
In Table 1, the clinical and biochemi-
cal characteristics of type 2 diabetic pa-
tients subdivided according to GAD
and/or IA-2(256–760) antibody positivity
are reported and compared. Four groups
of type 2 diabetic patients are shown:
patients positive for both GAD and IA-
2(256–760) antibodies [GADA
+/IA-2(256–760)A
+],
patients positive for GAD and negative
for IA-2(256–760) antibodies [GADA
+/
IA-2(256–760)A
2], patients positive for
IA-2(256–760) antibodies and negative for
GADA [GADA2/IA-2(256–760)A
+], and pa-
tients negative for both antibodies
[GADA2/IA-2(256–760)A
2].
Patients positive for both antibodies
[GADA+/IA-2(256–760)A
+], as expected,
showed the highest degree of autoim-
munity; IA-2IC, ZnT8, and TPO antibodies
were significantly higher in these pa-
tients compared with the other groups
(IA-2IC and ZnT8: P # 0.005 for all; TPO:
P # 0.03 for all). Considering the bio-
chemical and anthropometric charac-
teristics, we observed that, with the
only exception the age at diagnosis
(P = 0.016), patients positive for both
antibodies [GADA+/IA-2(256–760)A
+]
showed a phenotype substantially simi-
lar to that of patients positive for GADA
only [GADA+/IA-2(256–760)A
2]; they dif-
fered, instead, from the other two
groups, GADA2/IA-2(256–760)A
+ and
GADA2/IA-2(256–760)A
2, regarding BMI
(P , 0.0001 for both) and waist circum-
ference (P = 0.02 and P = 0.01, respec-
tively). Fasting glucose and uric acid
were significantly different between
GADA+/IA-2(256–760)A
+ and GADA2/
IA-2(256–760)A
2 (P = 0.04 and P = 0.01,
respectively).
When comparingGADA+/IA-2(256–760)A
2
and GADA2/IA-2(256–760)A
+ among them-
selves, we observed that BMI, waist
circumference, total cholesterol, and
Figure 1—Frequencies of GADA and protein tyrosine phosphatase IA-2As (IA-2256–760A and IA-2ICA) in 1,850 type 2 diabetic patients according to
BMI.
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uric acid levels were significantly lower
in GADA+/IA-2(256–760)A
2 patients than
in GADA2/IA-2(256–760)A
+ patients (P,
0.0001, P = 0.001, P = 0.01, and P =
0.003, respectively). Furthermore,
HDL cholesterol and TPO antibodies
were significantly higher in GADA+/
IA-2(256–760)A
2 patients than in GADA2/
IA-2(256–760)A
+ patients (P = 0.04 for
both). On the other hand, findings
were similar when GADA2/IA-2(256–760)A
+
patients and GADA2/IA-2(256–760)A
2
patients were compared, as no statis-
tically significant differences were
observed, with the only exception IA-
2ICA frequency (P = 0.002), showing
that patients positive for IA-2(256–760)A
only have a phenotype substantially
resembling that of a classical obese
patient with type 2 diabetes. Among
120 type 2 diabetic patients positive
for GADA, IA-2ICA, and IA-2(256–760)A
subdivided into three groups according
to BMI (,25, $25 to ,30, and $30
kg/m2), decreasing frequencies of ZnT8
antibody with increasing BMI (P = 0.01
for trend) were observed (data not
shown).
In the prospectively evaluated sub-
group of antibody-positive patients in
whom the risk of progression to insulin
therapy during a 7-year follow-up was
analyzed (n = 53), a significantly higher
number of GADA+/IA-2(256–760)A
+ and
GADA+/IA-2(256–760)A
2 patients (61.5%,
n = 8 of 13; and 62.5%, n = 15 of 24)
required insulin treatment compared
with GADA2/IA-2(256–760)A
+ (n = 0 of
16) patients (P = 0.0001, odds ratio
51.00 [95% CI 2.51–1,035.75]; and P =
0.0005, odds ratio 47.32 [2.52–888.45],
respectively).
CONCLUSIONS
In the current study, we demonstrated
that in patients with type 2 diabetes,
the prevalence of the type 1 diabetes–
specific GAD, IA-2IC(605–979), and IA-
2(256–760) autoantibodies significantly
decreased as BMI increased from ,25
to$30 kg/m2. Of particular interest, we
observed that, in islet autoantibody-
positive patients, the frequency of IA-
2(256–760)A significantly increased as
BMI increased so that it became the
most prevalent antibody in patients
with BMI $30 kg/m2. In addition, pres-
ence of the IA-2(256–760)A, when not as-
sociated with GADA (as was the case in
$80% of antibody-positive patients
with BMI .25 kg/m2), identified a phe-
notype resembling a classical obese
patient with type 2 diabetes, with signif-
icantly higher BMI, waist circumfer-
ence, total cholesterol, and uric acid
level and a lower frequency of HDL
cholesterol and TPO antibody positivity
than patients positive for GADA alone.
We have also found that none of the
16 patients positive for IA-2(256–760)A
alone progressed to insulin therapy re-
quirement during 7 years of follow-up
compared with 61.5% (8 of 13) of pa-
tients positive for both antibodies and
62.5% (15 of 24) of patients positive for
GADA alone. Based on these findings, if
we accept to define LADA as proposed
by Fourlanos et al. (19), a form of diabe-
tes diagnosed as type 2 but that
presents positivity for at least one anti-
body associated to type 1 diabetes [in-
deed, we previously demonstrated (7)
that autoantibodies to IA-2(256–760) are
present in 30% of type 1 diabetic chil-
dren and 40% of type 1 diabetics adult
patients], we have to conclude that
LADA is a quite heterogeneous disease,
ranging from patients with high GADA
titer and “clear signs of ongoing autoim-
munity” to patients positive only for
IA-2(256–760) and with a relatively mild au-
toimmune reactivity. Furthermore, as
previously emphasized by Brooks-Worrel
and Palmer (20), islet autoantibodies
used so far to identify LADA patients are
only those islet autoantibodies first iden-
tified in type 1 diabetes. The original de-
tection of IA-2(256–760) autoantibodies
in patients phenotypically resembling
Figure 2—Frequencies of GADA and protein tyrosine phosphatase IA-2As (IA-2256–760A and IA-2ICA) in 120 autoantibody-positive type 2 diabetic
patients according to BMI.
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type 2 diabetic (6) could help in classify-
ing LADA more accurately, recognizing
the wide heterogeneity of this form of
diabetes.
Our results, suggesting a lower de-
gree of islet destructive autoimmunity
in subjects positive only for IA-2(256–760)
and demonstrating a higher frequency
of these antibodies in obese patients
with type 2 diabetes, raise questions
about the real meaning of such autoanti-
bodies directed against this specific IA-2
epitope.
An intriguing hypothesis is that such
humoral autoimmune response may
be secondary to a chronic inflamma-
tion process associated to b-cell dam-
age, which occurs in obese patients
with type 2 diabetes (20). Visceral obe-
sity is one of the main risk factors for
type 2 diabetes. Indeed, evidence sup-
ports the concept that chronic inflam-
mation (low-grade inflammation),
which characterizes visceral obesity,
is involved in the pathogenesis of in-
sulin resistance and type 2 diabetes
(21), through the contribution of sev-
eral proinflammatory cytokines, inter-
leukin (IL)-1b (22), IL-6 (23), leptin,
and tumor necrosis factor-a (24),
implicated in disrupting insulin signal-
ing, causing insulin resistance.
Increasing evidence has demon-
strated that this chronic inflammation,
characterized by islet-associated ex-
pression of cytokines, including IL-1
(25) and IL-6 (26), hyperglycemia, che-
mokines (27), and dyslipidemia (28) act
together in determining an inflamma-
tory process in the islets of patients
with type 2 diabetes. The presence of
these inflammatory mediators in pa-
tients with type 2 diabetes has been
also implicated in b-cell apoptosis (29).
Cellular inflammation in the islets of
obese patients with type 2 diabetes is
therefore characterized by the presence
of cytokines, apoptotic cells, amyloid
deposits, and eventually fibrosis and im-
mune cell infiltration. The presence of
immune cells (20,26) suggests that
immune-mediated islet damage may
indeed be a component of type 2
diabetes.
Low-grade inflammation that charac-
terizes obese patients could also deter-
mine acquired autoimmunity against
b-cells; however, this adaptive autoim-
mune response, although present, may
not necessarily have a pathogenic role in
the development of type 2 diabetes
(14). Indeed, the inflammatory process
in adipose tissue seems to be similar in
all insulin-resistant individuals with obe-
sity, regardless of whether or not they
progress to develop type 2 diabetes
(30).
Taking into account that the develop-
ment of islet autoimmunity in obese pa-
tients with type 2 diabetes may be
related to the established systemic in-
flammation associated with obesity,
the real meaning of the specific immune
reactivity against the 256–760 domain
of IA-2 protein needs to be further in-
vestigated. Tyrosine phosphatase–
related IA2 protein (amino acids 1–979),
one of the major autoantigens in type
1 diabetes and target of both humoral
and T-cell reactivity, is an enzymatic in-
active transmembrane glycoprotein lo-
calized in the secretory granules of
peptide-secreting endocrine cells (31).
Although the real function of this pro-
tein is largely unknown, there is evi-
dence that its association with other
proteins may favor a link between secre-
tory granules with a cytoskeleton, thus
affecting exocytosis. To date, IA-2As are
detected using sensitive and specific
Figure 3—Venn diagram of autoantibody combinations [GADA and protein tyrosine phosphatase IA-2As (IA-2256–760A and IA-2ICA)] in 120
autoantibody-positive type 2 diabetic patients, subdivided according to BMI.
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radioimmunoassays, differing in which
of the radiolabeled IA-2 constructs
were used, usually chosen among the
full-length IA-2FL(1–979), the truncated
NH2 terminally spliced IA-2 variant lack-
ing exon 13, the IA-2BDC(aa256–556:630–979),
and the intracytoplasmic IA-2IC(605–979)
construct (32,33). Although all of these
constructs are sensitive and specific,
the IA-2IC(605–979) construct has dem-
onstrated the highest sensitivity in
patients with newly diagnosed type 1
diabetes and in patients with pre–type
1 diabetes, suggesting its use for type
1 diabetic screening (6).
Previous studies have demonstrated
that IA-2A in type 1 diabetes is directed
against multiple epitopes of the intra-
cellular cytoplasmic portion of the pro-
tein (amino acids 601–979) located in
the juxtamembrane region and the
COOH-terminal domain (amino acids
630–979) (34–37).
In contrast, we have recently found
that, in islet autoantibody–positive
type 2 diabetic patients, the immunore-
activity against IA-2IC(605–979) is present
at lower frequency than that toward the
IA-2(256–760) fragment.
Of note, this immunoreactivity, fre-
quent in obese subjects, is located in a
segment of the IA-2 molecule comprising
the extracellular portion of the protein.
In light of such evidence, we hypothe-
size that islet inflammation occurring in
type 2 diabetes may favor the presenta-
tion of extracellular antigens to antigen-
presenting cells in an early stage of the
inflammatory process.
In conclusion, we have demon-
strated that autoantibodies against
the IA-2(256–760) protein appear to repre-
sent an antibody marker that mainly
identifies a clinical phenotype of patients
very similar to that of classic obese type
2 diabetes. The presence of this anti-
body could underline a mechanism of
eliciting a humoral immune response dif-
ferent from that occurring in “classical”
autoimmune diabetes and possibly sec-
ondary to chronic systemic inflammation
associated with obesity as well as to islet
inflammation associated with type 2
diabetes.
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Appendix
NIRAD follow-up investigators. G. Adda and
S. Di Lembo, S. Giuseppe Ospedale (Milano);
A. Aglialoro and A. Cattaneo, Villa Scassi (Genova);
R. Anichini, Presidio Ospedaliero (Pistoia);
A. Arcangeli, ASL 4 (Prato);M.L. Arpi, Endocrinologia,
Ospedale Garibaldi Nesima (Catania); R.G. Bardini,
Universita` (Firenze); P. Basciano, Ospedale
Sant’Antonio Abate Erice (Trapani); M. Bracaccia
and S. Pistoni, Ospedale S. Maria della Stella di
Orvieto (Terni); D. Bracaglia, Centro Diabetologico
ASL Roma B (Roma); V. Borzı`, Ospedale Vittorio
Emanuele II (Catania); F. Cannata`, Ospedale S.Maria
della Croci (Ravenna); G. Capitano, ASL 2 (Salerno);
M. Cignarelli and S. Piemontese, Universita` (Foggia);
G.Capuano,CentroDiabetologico (Salerno); S.Carro,
Centro Antidiabetico ASL 5 (La Spezia); C. Cazzalini,
Ospedale Maggiore (Crema); L. Cocco, Diabetologia
e Malattie Metaboliche, Ospedale Cardarelli,
(Campobasso); A.M. Ciccarone, Dipartimento di
Endocrinologia eMetabolismoOspedale di Cisanello
(Pisa); G. Cicioni, ASL 4 (Terni); E. Cossu and F. Sano,
Centro Diabetologico e Malattie Metaboliche,
Table 1—Clinical and biochemical characteristics and antibody frequencies in type 2 diabetic patients grouped according to
GADA and protein tyrosine phosphatase [IA-2(256–760)A] positivity
1 2 3 4
GADA+/IA-2(256–760)A
+
(n = 20)
GADA+/IA-2(256–760)A
2
(n = 58)
GADA2/IA-2(256–760)A
+
(n = 42)
GADA2/IA-2(256–760)A
2
(n = 1,730)
Age at diagnosis (years) 44.0 6 15.6 53.5 6 14.3 54.6 6 11 56.4 6 11.2
Duration of disease (months) 21.5 6 20.3 23.5 6 20.7 24.6 6 19.8 24.7 6 19
BMI (kg/m2) 24.9 6 3.9 26.1 6 4.2 30.8 6 6.4 30.1 6 5.7
Waist circumference (cm) 92.2 6 7.6 91.2 6 13.7 101.1 6 13.7 99.2 6 15.8
Fasting glucose (mg/dL)* 169.1 6 57.8 163.2 6 68 143.6 6 45.8 146.3 6 43
Total cholesterol (mg/dL) 174.9 6 65.8 152.1 6 58.8 183.7 6 56 179.6 6 73.2
HDL (mg/dL) 51.4 6 11 54.0 6 28.2 44.7 6 12.4 48.6 6 18.7
Triglycerides (mg/dL)* 147.8 6 69.5 162.0 6 70.6 184.6 6 83.2 180.8 6 95.6
HbA1c (%) 7.7 6 1.9 7.7 6 2.3 7.1 6 1.6 6.9 6 3.7
HbA1c (mmol/mol) 61.0 6 21.1 61.0 6 21.5 54.0 6 20.7 52.0 6 23.8
Uric acid (mg/dL) 4.1 6 2.1 4.0 6 0.8 5.2 6 1.2 5.2 6 1.5
IA-2IC
+ 13/20 (65) 7/58 (12) 1/42 (2.4) 0/1,730 (0)
ZnT8+ 10/20 (50) 5/58 (8.6) 0/42 (0) 2/240 (0.83)
tTGA+ 0/20 (0) 2/58 (3.4) 0/42 (0) 1/240 (0.41)
TPO+ 13/20 (65) 20/58 (34.4) 6/42 (14.2) 20/240 (8.3)
Data are mean6 SD unless otherwise indicated. 1 vs. 2: age at diagnosis, P = 0.016; IA-2IC
+ and ZnT8+, P, 0.0001; and TPO+ P = 0.03. 1 vs. 3: age at
diagnosis and ZnT8+ P = 0.005; BMI, IA-2IC
+, and TPO+, P, 0.0001; waist circumference, P = 0.02; tTGA+, P = not calculable. 1 vs. 4: age at diagnosis, P =
0.0002; BMI, IA-2IC
+, ZnT8+, and TPO+, P, 0.0001; waist circumference and uric acid, P = 0.01; and fasting glucose, P = 0.04. 2 vs. 3: BMI, P, 0.0001;
waist circumference, P = 0.001; total cholesterol, P = 0.01; HDL and TPO+, P = 0.04; and uric acid, P = 0.003. 2 vs. 4: BMI, waist circumference, IA-2IC
+,
and TPO+, P, 0.0001; total cholesterol, P = 0.009; uric acid, P = 0.0012; and ZnT8+, P = 0.002. 3 vs. 4: IA-2IC
+, P = 0.002. *Data were log transformed.
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